DANTE is a multicenter phase II trial that is comparing perioperative atezolizumab (anti-PD-L1) and FLOT chemotherapy against FLOT alone in patients with operable LAGC regardless of PD-L1 status (≥cT2 or N+ GC/GEJC) [77]. The gene discussed is CD274; the disease is gastric cancer.